Pregabalin Capsule
Product Images NDC 71205-677

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-677). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure diagram of pregabalin showing its molecular arrangement including the carboxylic acid (CO2H) and amino (NH2) functional groups connected to a branched carbon backbone.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The y-axis indicates the percent of patients improved, while the x-axis represents percent improvement in pain from baseline.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph illustrating percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. Two lines compare patients taking Pregabalin 100 mg three times a day versus a placebo, showing higher improvement rates for the Pregabalin group across the range of pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin 04)

Line graph showing percent of patients improved plotted against percent improvement in pain from baseline. It compares Pregabalin at 75 mg, 150 mg, and 300 mg taken two times a day with placebo, illustrating variations in patient improvement across these dosages.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, with Percent Improvement in Pain on the x-axis and Percent of Patients Improved on the y-axis.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line chart comparing the percent of patients improved over a range of improvement percentages for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The x-axis represents percent improvement from greater than 0 to 100, and the y-axis shows the percent of patients improved from 0 to 100. Three lines illustrate the outcomes for each treatment group across the improvement scale.*

FDA Label Image

Figure 6 (Pregabalin 07)

A bar chart comparing responder rates (%) across different dosages of Pregabalin versus placebo in two studies labeled Study E1 and Study E3. The x-axis lists placebo and Pregabalin doses with corresponding patient counts, while the y-axis shows responder rate percentages. Study E1 includes placebo and daily doses from 50 mg to 600 mg, and Study E3 includes placebo and 300 mg/day and 600 mg/day doses, illustrating higher responder rates with increasing Pregabalin dose.*

FDA Label Image

Figure 7 (Pregabalin 08)

A dose-response graph showing seizure reduction as the median percentage change from baseline against the dose (mg/day). The chart displays data points from three studies labeled E1 BID, E2 TID, and E3 BID and TID, with p-values indicating statistical significance for the changes observed at various doses up to 600 mg/day compared to placebo.*

FDA Label Image

Figure 9 (Pregabalin 09)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 600 mg daily dose, 450 mg daily dose, 300 mg daily dose, and placebo, illustrating patient response over a range of pain improvement percentages.*

FDA Label Image

Figure 10 (Pregabalin 10)

A Kaplan-Meier survival curve graph showing the estimated percentage of subjects without LTR (likely loss to relapse) over time in days. Two lines represent Pregabalin and Placebo groups, with the Pregabalin group maintaining a higher percentage of subjects without LTR across the 180 days.*

FDA Label Image

Figure 11 (Pregabalin 11)

A line graph depicting the percent of subjects improved from baseline to Week 12 BOCF for Pregabalin and Placebo groups. The horizontal axis shows the percent improved from baseline, ranging from 0 to over 90%, and the vertical axis shows the percent of subjects improved, from 0 to 100%. Pregabalin results appear as a solid line generally higher than the dotted line representing Placebo results.*

FDA Label Image

Figure 12 (Pregabalin 12)

A line graph comparing the percent of subjects improved from baseline to Week 16 on the BOCF (Baseline Observation Carried Forward) method. The x-axis shows percent improved, and the y-axis shows percent of subjects improved. Two lines represent different groups labeled Pregabalin and Placebo, illustrating their respective improvement trends over the course of the study.*

FDA Label Image

71205-677-60 (Pregabalin 15)

The packaging label for Pregabalin 75 mg capsules from Proficient Rx LP, containing 60 capsules. The label includes dosage form and strength, directions to dispense the medication guide, capsule description (white to off white hard gelatin filled with orange opaque colored cap and white opaque colored body imprinted with 'SG' and '352'), product ID QP067760, manufacturer SciGen Biologics Inc., and storage instructions at 25°C (77°F). The label also features NDC codes, controlled substance schedule C-V, and packaging details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.